The U.S. intravenous immunoglobulin (IVIG) market was valued at USD 5.74 billion in 2022 and is projected to expand at a 7.7% CAGR from 2023 to 2030. Growth is being supported by increasing demand for immunoglobulin replacement therapy among patients with Primary Immunodeficiency Diseases (PIDD), along with the approval of new IVIG products that are broadening available treatment options.

What Is Driving IVIG Demand in the U.S.?

The rising need for immunoglobulin replacement therapies remains a central growth factor for the U.S. IVIG market. IVIG is used across a broad range of autoimmune, neurological, hematological, and immunodeficiency-related conditions. The U.S. FDA has approved IVIG for multiple disorders, while physicians also use the therapy in several off-prescription applications, including Guillain-Barre syndrome, myasthenia gravis, and multifocal motor neuropathy.

The increasing clinical use of IVIG has contributed to higher utilization across specific disease categories. For example, the quantity of IVIG units used for treating chronic inflammatory demyelinating polyneuropathy (CIDP) has increased significantly, reflecting continued demand for immunoglobulin-based treatment.

Home Infusion Is Reshaping Treatment Delivery

A notable shift in the U.S. IVIG landscape is the growing adoption of home infusion therapy. The pandemic accelerated this transition as patients and healthcare providers sought safer ways to administer treatments outside traditional healthcare settings.

Home-based administration can reduce exposure to healthcare environments, which is particularly relevant for immunocompromised patients with weakened immune systems. The adoption of home infusion is expected to remain an important component of IVIG treatment delivery beyond the pandemic period.

Download a free sample report or claim your copy of this full market intelligence report

COVID-19 Exposed Vulnerabilities in the Plasma Supply Chain

The COVID-19 pandemic significantly disrupted IVIG market dynamics in the U.S. Increased demand for plasma-derived products during the early stages of the pandemic placed substantial pressure on the immunoglobulin supply chain. At the same time, plasma donations declined, further tightening supply.

Because plasma fractionation requires considerable processing time, these disruptions became increasingly visible in early 2021. The resulting shortage of immunoglobulin products highlighted the importance of maintaining a stable plasma collection and fractionation infrastructure.

Companies are also exploring IVIG therapies as potential treatment options for additional conditions. Regulatory approvals for such applications in the coming years could contribute to broader treatment adoption.

High Treatment Costs Remain a Major Barrier

Despite the clinical benefits associated with IVIG, treatment cost remains a significant constraint on adoption in the U.S. According to NCBI data cited for 2021, the average cost per IVIG treatment session was approximately USD 9,720. At an average of 4.3 sessions per month, the corresponding monthly treatment cost was approximately USD 41,796.

The financial burden is particularly significant for patients with CIDP. The average annual treatment cost for a CIDP patient exceeds USD 136,000, making access more difficult for individuals without adequate insurance coverage or Medicare.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Product Approvals Are Expanding Treatment Options

Changing patient needs are encouraging IVIG manufacturers to invest in product development, regulatory approvals, and new product launches. These activities are expanding the range of available therapies and addressing demand across different patient populations.

In July 2021, the FDA approved Octagam 10% for the treatment of dermatomyositis in adults. The approval expanded the available treatment options for patients with this condition and strengthened the role of IVIG in managing additional disease indications.

Another notable development occurred in April 2023, when Takeda Pharmaceutical Company Limited received FDA approval to expand the use of Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase (Hyqvia). The therapy is used for the treatment of primary immunodeficiency in patients aged 2 years and older.

Competitive Landscape

Companies operating in the U.S. IVIG market are pursuing several strategies to strengthen their positions, including product innovation, new product launches, research and development, regulatory approvals, and mergers and acquisitions.

Prominent companies identified in the U.S. intravenous immunoglobulin market include:

• Biotest AG
• China Biologics Products Holdings, Inc.
• Octapharma AG
• LFB Biotechnologies S.A.S
• Takeda Pharmaceutical Company Limited
• Bio Products Laboratory Ltd.
• Pfizer, Inc.
• CSL

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.
• Prism AI: Market Intelligence with Cited Research -

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.